Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.

about

Magnetic Mesoporous Calcium Sillicate/Chitosan Porous Scaffolds for Enhanced Bone Regeneration and Photothermal-Chemotherapy of Osteosarcoma.

P2860

Q55179549-03984F9A-608C-487A-B56B-4AAE0511BBB7

P2860

Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.

Item

http://www.wikidata.org/entity/Q47750583

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Anti-glypican-1 antibody-drug ...... itive uterine cervical cancer.

@en

Anti-glypican-1 antibody-drug ...... itive uterine cervical cancer.

@nl

type

Item

label

Anti-glypican-1 antibody-drug ...... itive uterine cervical cancer.

@en

Anti-glypican-1 antibody-drug ...... itive uterine cervical cancer.

@nl

prefLabel

Anti-glypican-1 antibody-drug ...... itive uterine cervical cancer.

@en

Anti-glypican-1 antibody-drug ...... itive uterine cervical cancer.

@nl

P1476

Anti-glypican-1 antibody-drug ...... itive uterine cervical cancer.

@en

P2093

Eiichi Morii

http://www.w3.org/2001/XMLSchema#string

Kosuke Hiramatsu

http://www.w3.org/2001/XMLSchema#string

Satoko Matsuzaki

http://www.w3.org/2001/XMLSchema#string

Satoshi Nojima

http://www.w3.org/2001/XMLSchema#string

Seiji Mabuchi

http://www.w3.org/2001/XMLSchema#string

Shinya Matsuzaki

http://www.w3.org/2001/XMLSchema#string

Tadashi Kimura

http://www.w3.org/2001/XMLSchema#string

Tomoharu Ohkawara

http://www.w3.org/2001/XMLSchema#string

Yutaka Ueda

http://www.w3.org/2001/XMLSchema#string

P2860

Glypicans

The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer

Global cancer statistics, 2012

Cancer statistics, 2016

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

Improved survival with bevacizumab in advanced cervical cancer

Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma.

Glypicans: proteoglycans with a surprise.

P304

1056-1066

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.31124

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

142

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29055044

http://www.w3.org/2001/XMLSchema#string

Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.

about

P2860

P2860

Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698